Malignant Genitourinary System Neoplasm

cancer family

Identifier: CI-CAN-00000233
Entity page: /cancer/malignant-genitourinary-system-neoplasm ↗
Edges: 15,722

Neighbours: 15 genes23 drugs10 trials
Drawn: 48 of 48 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Genitourinary System Neoplasm approved for …APPROVED_FORderived15 of 137show all (up to 200)
← approved for	Denosumabmonoclonal antibody FDA (US) · approved · 2025-10-29 · to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer	—	approved	Malignant Prostate Neoplasm	1	Regulatory	openfda	graph →
approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Mutation OlaparibFDA US 2017-08-1755 active / 123 trials
Curatedlevel Asensitivity· support 7civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Ovarian Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm +1
BRCA2 Mutation OlaparibFDA US 2017-08-1755 active / 123 trials
Curatedlevel Asensitivity· support 6civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 14 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Ovarian Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm +1
BRCA2 Mutation RucaparibFDA US 2016-12-194 active / 29 trials
Curatedlevel Asensitivity· support 5civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 14 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Malignant Ovarian Neoplasm, Castration-Resistant Prostate Carcinoma
BRCA1 Mutation RucaparibFDA US 2016-12-194 active / 29 trials
Curatedlevel Asensitivity· support 5civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Malignant Ovarian Neoplasm, Castration-Resistant Prostate Carcinoma
ATM Mutation OlaparibFDA US 2017-08-1755 active / 123 trials
Curatedlevel Asensitivity· support 2civicObservedATM altered in 4.2% (86 / 2,069 cases, largest of 16 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Malignant Prostate Neoplasm, Castration-Resistant Prostate Carcinoma
CDK12 Mutation OlaparibFDA US 2017-08-1755 active / 123 trials
Curatedlevel Asensitivity· support 1civicObservedCDK12 altered in 5.7% (118 / 2,069 cases, largest of 9 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
CHEK2 mutation OlaparibFDA US 2017-08-1755 active / 123 trials
Curatedlevel Asensitivity· support 1civicObservedCHEK2 altered in 4.2% (21 / 499 cases)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BARD1 Mutation OlaparibFDA US 2017-08-1755 active / 123 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BARD1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Genitourinary System Neoplasm altered in cohorts of …ALTERED_INderived15 of 881show all (up to 200)
← altered in cohorts of	COL7A1 450 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	GLB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PLXNB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATRIP 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCDC51 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDC25A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CELSR3 449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	FBXW12 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHATL 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	IP6K2 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NCKIPSD 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PFKFB4 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PRKAR2A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTH1R 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SCN5A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →

Malignant Genitourinary System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 345show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 485 trials (106 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	485	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 445 trials (109 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	445	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 372 trials (93 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	372	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 346 trials (171 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	346	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 321 trials (63 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	321	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 278 trials (85 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	278	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 250 trials (64 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	250	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 208 trials (87 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	208	Observed	clinicaltrials	graph →
→ investigated in trials for	Enzalutamidesmall molecule 204 trials (69 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	204	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 194 trials (46 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	194	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 150 trials (40 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	150	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 145 trials (28 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	145	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 143 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	143	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 130 trials (29 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	130	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 123 trials (55 active) · roll-up of the cancer and its descendants	—	—	Malignant Genitourinary System Neoplasm	123	Observed	clinicaltrials	graph →

Malignant Genitourinary System Neoplasm studied in …STUDIED_INderived10 of 14,359show all (up to 200)
→ studied in	NCT00034216recruiting Collection of Blood From Patients With Cancer · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00043472completed Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01441089recruiting Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02489318Phase 3 · active not recruiting A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03668340Phase 2 · active not recruiting AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma · condition mapped ALIAS · 14,359 trials mapped (4,135 active)	—	—	Malignant Uterine Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03762733enrolling by invitation Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04065009Phase 3 · active not recruiting The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer · condition mapped CURATED_BROADER · 14,359 trials mapped (4,135 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped CURATED_BROADER · 14,359 trials mapped (4,135 active)	—	—	Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04235764recruiting En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device · condition mapped CURATED_EXACT · 14,359 trials mapped (4,135 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →